enGene Therapeutics (ENGN) Other Working Capital Changes (2024 - 2026)
enGene Therapeutics (ENGN) posted quarterly Other Working Capital Changes of -$282000.0 for Q2 2026, down 452.5% year-over-year from $80000.0 in Q2 2025, and down 823.08% quarter-over-quarter from $39000.0 in Q1 2026.
enGene Therapeutics (ENGN) Other Working Capital Changes (2024 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Other Working Capital Changes for 3 consecutive years, with -$282000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Working Capital Changes fell 452.5% year-over-year to -$282000.0; the TTM figure through Apr 2026 stood at $119000.0 (up 169.19% YoY), while the FY2025 annual figure was $274000.0, up 659.18% from the prior year.
- Other Working Capital Changes slipped to -$282000.0 in Q2 2026 per ENGN's latest filing, from $39000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $3.9 million in Q4 2024 and bottomed at -$2.0 million in Q4 2025.
- Historically, Other Working Capital Changes has averaged $738000.0 across 4 years, with a median of $698000.0 in 2023.
- On a YoY basis, Other Working Capital Changes climbed as much as 4100.0% in 2025 and fell as far as 554.05% in 2025.
- enGene Therapeutics' Other Working Capital Changes stood at -$43000.0 in 2024, then soared by 637.21% to $231000.0 in 2025, then slumped by 222.08% to -$282000.0 in 2026.
- Business Quant data shows ENGN's Other Working Capital Changes at -$282000.0 in Q2 2026, $39000.0 in Q1 2026, and $231000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | enGene Therapeutics | 124.46 Mn | 124.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -282,000.00 |
| Apr 30, 2026 | -282,000.00 |
| Apr 30, 2026 | -282,000.00 |
| Jan 31, 2026 | 39,000.00 |
| Jan 31, 2026 | 39,000.00 |
| Jan 31, 2026 | 39,000.00 |
| Oct 31, 2025 | 231,000.00 |
| Oct 31, 2025 | 231,000.00 |
| Oct 31, 2025 | 231,000.00 |
| Jul 31, 2025 | 131,000.00 |
| Jul 31, 2025 | 131,000.00 |
| Jul 31, 2025 | 131,000.00 |
| Apr 30, 2025 | 80,000.00 |
| Apr 30, 2025 | 80,000.00 |
| Apr 30, 2025 | 80,000.00 |
| Jan 31, 2025 | -168,000.00 |
| Jan 31, 2025 | -168,000.00 |
| Jan 31, 2025 | -168,000.00 |
| Oct 31, 2024 | -43,000.00 |
| Oct 31, 2024 | -43,000.00 |